MX2022004808A - Métodos para tratar el cáncer de próstata. - Google Patents
Métodos para tratar el cáncer de próstata.Info
- Publication number
- MX2022004808A MX2022004808A MX2022004808A MX2022004808A MX2022004808A MX 2022004808 A MX2022004808 A MX 2022004808A MX 2022004808 A MX2022004808 A MX 2022004808A MX 2022004808 A MX2022004808 A MX 2022004808A MX 2022004808 A MX2022004808 A MX 2022004808A
- Authority
- MX
- Mexico
- Prior art keywords
- prostate cancer
- methods
- treating prostate
- treatment
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962924655P | 2019-10-22 | 2019-10-22 | |
| US201962945418P | 2019-12-09 | 2019-12-09 | |
| US202063028843P | 2020-05-22 | 2020-05-22 | |
| US202063032453P | 2020-05-29 | 2020-05-29 | |
| PCT/US2020/056684 WO2021081108A1 (en) | 2019-10-22 | 2020-10-21 | Methods of treating prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022004808A true MX2022004808A (es) | 2022-06-08 |
Family
ID=73449188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022004808A MX2022004808A (es) | 2019-10-22 | 2020-10-21 | Métodos para tratar el cáncer de próstata. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20210113557A1 (https=) |
| EP (1) | EP4048236A1 (https=) |
| JP (2) | JP7716396B2 (https=) |
| KR (1) | KR20220087482A (https=) |
| CN (1) | CN115135313A (https=) |
| AU (1) | AU2020370150A1 (https=) |
| CA (1) | CA3158411A1 (https=) |
| IL (1) | IL292359A (https=) |
| MX (1) | MX2022004808A (https=) |
| WO (1) | WO2021081108A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| CN110506039A (zh) | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
| CR20220630A (es) | 2020-05-09 | 2023-01-23 | Arvinas Operations Inc | Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo |
| WO2022048605A1 (zh) * | 2020-09-04 | 2022-03-10 | 南昌奥瑞药业有限公司 | 一种杂环化合物、其制备方法、中间体、组合物以及应用 |
| JP2023547084A (ja) * | 2020-10-21 | 2023-11-09 | アルビナス・オペレーションズ・インコーポレイテッド | アンドロゲン受容体タンパク質の標的分解のための化合物および方法 |
| JP2023552818A (ja) * | 2020-12-11 | 2023-12-19 | アルビナス・オペレーションズ・インコーポレイテッド | 前立腺癌を治療する方法 |
| CN113620931B (zh) * | 2021-09-13 | 2023-06-09 | 中国海洋大学 | 一种雄激素受体抑制剂及其用途 |
| US20250248999A1 (en) * | 2022-04-21 | 2025-08-07 | Arvinas Operations, Inc. | Bavdegalutamide and combinations thereof for use in treating prostate cancer |
| WO2024233696A1 (en) * | 2023-05-09 | 2024-11-14 | Arvinas Operations, Inc. | Bavdegalutamide for treating prostate cancer without ar l702h mutation |
| TW202535392A (zh) | 2023-12-08 | 2025-09-16 | 美商亞文納營運公司 | 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US20140255413A1 (en) * | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| US20140287039A1 (en) * | 2013-03-15 | 2014-09-25 | Iceutica Inc. | Abiraterone Acetate Formulation |
| WO2015114314A1 (en) * | 2014-01-28 | 2015-08-06 | Cipla Limited | Pharmaceutical composition comprising abiraterone |
| RU2738833C9 (ru) * | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| WO2016081472A1 (en) * | 2014-11-21 | 2016-05-26 | Biohaven Pharmaceutical Holding Company Ltd. | Sublingual formulation of riluzole |
| CN109310664A (zh) * | 2016-06-10 | 2019-02-05 | 田纳西大学研究基金会 | 选择性雄激素受体降解剂(sard)配体和其使用方法 |
| JOP20190067A1 (ar) * | 2016-09-30 | 2019-03-28 | Janssen Pharmaceutica Nv | طُرق تشخيص وعلاج سرطان البروستاتا النقيلي المقاوم للإخصاء والمقاوم أو الحساس لأبيراتيرون أسيتات-الهرمون القشري السكري |
| CN110506039A (zh) * | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
-
2020
- 2020-10-21 KR KR1020227016404A patent/KR20220087482A/ko not_active Ceased
- 2020-10-21 MX MX2022004808A patent/MX2022004808A/es unknown
- 2020-10-21 CA CA3158411A patent/CA3158411A1/en active Pending
- 2020-10-21 CN CN202080080511.2A patent/CN115135313A/zh active Pending
- 2020-10-21 WO PCT/US2020/056684 patent/WO2021081108A1/en not_active Ceased
- 2020-10-21 IL IL292359A patent/IL292359A/en unknown
- 2020-10-21 AU AU2020370150A patent/AU2020370150A1/en active Pending
- 2020-10-21 US US17/075,808 patent/US20210113557A1/en not_active Abandoned
- 2020-10-21 EP EP20807571.3A patent/EP4048236A1/en not_active Withdrawn
- 2020-10-21 JP JP2022523564A patent/JP7716396B2/ja active Active
-
2022
- 2022-12-21 US US18/085,869 patent/US20230128132A1/en not_active Abandoned
-
2025
- 2025-07-18 JP JP2025120941A patent/JP2025157436A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7716396B2 (ja) | 2025-07-31 |
| JP2022553954A (ja) | 2022-12-27 |
| US20230128132A1 (en) | 2023-04-27 |
| CN115135313A (zh) | 2022-09-30 |
| AU2020370150A1 (en) | 2022-05-12 |
| US20210113557A1 (en) | 2021-04-22 |
| JP2025157436A (ja) | 2025-10-15 |
| CA3158411A1 (en) | 2021-04-29 |
| WO2021081108A1 (en) | 2021-04-29 |
| EP4048236A1 (en) | 2022-08-31 |
| IL292359A (en) | 2022-06-01 |
| KR20220087482A (ko) | 2022-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022004808A (es) | Métodos para tratar el cáncer de próstata. | |
| CL2023001655A1 (es) | Métodos para tratar el cáncer de próstata | |
| CO2022002729A2 (es) | Métodos de tratamiento del cáncer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrógenos | |
| BR112022022988A2 (pt) | Métodos de tratamento do câncer de próstata | |
| DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
| SA522432955B1 (ar) | Kras g12c مثبطات | |
| AR122783A2 (es) | Inhibidores de kras g12c y métodos para su uso | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| MX2022000271A (es) | Inhibidores de la quinasa progenitora hematopoyetica 1 y usos de los mismos. | |
| PH12019500214A1 (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| UY37133A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
| MX380798B (es) | Profármacos de alvocidib que tienen una biodisponibilidad aumentada. | |
| PH12019501896A1 (en) | Therapeutic dendrimers | |
| MX2024009926A (es) | Composiciones y metodos para tratar trastornos del snc. | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| MX2021006724A (es) | Compuestos de halo-alilamina y uso de los mismos. | |
| AR126849A1 (es) | Compuestos de quinazolina para tratamiento de enfermedad | |
| WO2017165822A8 (en) | Small molecule inhibitor of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | |
| CO2022015891A2 (es) | Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres | |
| MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
| JOP20240269A1 (ar) | حلقات كبيرة من إندازول و استخدامها | |
| CL2025001119A1 (es) | Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina |